TY - JOUR
T1 - Tumor-bound immunoglobulins
T2 - In situ expressions of humoral immunity
AU - Witz, Isaac P.
N1 - Funding Information:
The research of the author is supported by a grant from the United States-Israel Binational Science Foundation (B.S.F.), Jerusalem, Israel, and by Public Health Service contract No. 1 CB43858 from the Division of Cancer Biology and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
PY - 1977/1/1
Y1 - 1977/1/1
N2 - An accurate and precise evaluation of tumor-host relations is an essential prerequisite for a rational approach to cancer therapy, in particular immunotherapy, and to a correct assessment of prognosis. The host–tumor relationship is assessed mainly by the capacity of immune components, such as lymphocytes, macrophages, or antibodies, to react in vitro against tumor cells. It is noted that the expression of immunity is not equal in all sites of the body. It is significant to evaluate in situ tumor immunity concerning the immune-histology of the malignant area in relation to prognosis or treatment. This chapter summarizes the available data on the presence, properties, and functions of humoral immune components, mainly immunoglobulins, at the site of malignant tumors. It focuses on the studies that deal with nonlymphoid malignancies. Common methods used to detect tumor-associated immunoglobulins (TAIg) include (1) the treatment of tumor fragments with low pH buffers or with salt solutions of high molarity, (2) direct membrane immunofluorescence of tumor cells, (3) radioimmunofixation, and (4) mixed hemadsorption. The chapter considers several TAIg such as Ig class and IgG subclass.
AB - An accurate and precise evaluation of tumor-host relations is an essential prerequisite for a rational approach to cancer therapy, in particular immunotherapy, and to a correct assessment of prognosis. The host–tumor relationship is assessed mainly by the capacity of immune components, such as lymphocytes, macrophages, or antibodies, to react in vitro against tumor cells. It is noted that the expression of immunity is not equal in all sites of the body. It is significant to evaluate in situ tumor immunity concerning the immune-histology of the malignant area in relation to prognosis or treatment. This chapter summarizes the available data on the presence, properties, and functions of humoral immune components, mainly immunoglobulins, at the site of malignant tumors. It focuses on the studies that deal with nonlymphoid malignancies. Common methods used to detect tumor-associated immunoglobulins (TAIg) include (1) the treatment of tumor fragments with low pH buffers or with salt solutions of high molarity, (2) direct membrane immunofluorescence of tumor cells, (3) radioimmunofixation, and (4) mixed hemadsorption. The chapter considers several TAIg such as Ig class and IgG subclass.
UR - http://www.scopus.com/inward/record.url?scp=0017435927&partnerID=8YFLogxK
U2 - 10.1016/S0065-230X(08)60633-8
DO - 10.1016/S0065-230X(08)60633-8
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0017435927
VL - 25
SP - 95
EP - 148
JO - Advances in Cancer Research
JF - Advances in Cancer Research
SN - 0065-230X
IS - C
ER -
